Hormone therapy of the female Kallmann's Syndrome patient in the setting of a pulmonary embolism presents a challenge. A female with hypogonadotropic hypogonadism is usually presented with two treatment options -combined gonadal hormone replacement or pulsatile gonadotropin releasing hormone. When a patient incurs a contraindication to hormonal therapy, the management of their endocrine disorder becomes much more challenging. Providers and patients must consider the advantages and disadvantages to each treatment option, including the possibility of not treating at all. Given the lack of literature on this rare combination of events, herein we review Kallmann's Syndrome and its therapeutic options, as well as the hypercoagulability associated with hormone therapy to guide our decision-making process in a true case scenario.
Discussion
KS is a rare disorder, with an incidence ranging from 1:10,000 to 1:86,000, and a male to female ratio of roughly 4:1. 1 Characterized by hypogonadotropic hypogonadism and anosmia, KS patients are usually treated with hormone replacement regimens. The most common option in females not desiring immediate fertility is gonadal hormone replacement, as is done in their male counterparts. 2 Females are started on unopposed estradiol, and doses are gradually increased until normal menses occur. When breast development is perceived as optimal, a progestin is added for endometrial protection. At this point, the progestin therapy can be taken in a continuous or cyclical fashion at the discretion of the patient and provider. 3 The estrogen therapy however, should be continuous, as premature discontinuation can halt sexual maturity, initiate menopausal symptoms, and increase the risk of fractures in the developing female. 4 The challenge presented in our case is that hormone therapy is associated with significant hypercoagulability. According to the World Health Organization Medical Eligibility Criteria (WHO MEC) for use of combination oral contraceptives (COC), patients with a personal history of deep vein thrombosis, or pulmonary embolism are assigned risk category 4, a condition which represents an unacceptable health risk if the contraceptive method is used. 5 In order to adequately evaluate our patient's risk, we must evaluate existing treatment options for female hypogonadotropic hypogonadism, the most common being combined oral contraceptives (COC's). Many formulations of estrogen-progestin COC's are available today. Major characteristics that differentiate one formulation from another include the dosage of ethinyl estradiol (EE), the standard estrogen used in all COC's in the United States, and the generation of the progestin. The estrogen has changed significantly since COC's were first introduced in the United States in the mid 20 th century, as current COC's contain 5-10 times less estrogen than original formulations. 6 Although low-dose oral contraception has become common terminology, its origins are antiquated, as all of today's COC's in the US are manufactured with less than 50 mcg of EE. 7 Some formulations contain as little as 20 mcg of EE, though their ability to optimally inhibit ovulation has been debated. 8 Switching our patient to a lower EE-dose COC may offer a disadvantage in treating her KS and an advantage by decreasing her risk for future thrombotic events.
As discussed above, the role of estrogen therapy in the hypogonadotropic female is to maintain sexual maturity and maximize bone health. Data suggest the latter is optimized at a minimum dose of 30 mcg EE in endocrinologically normal patients taking COC's for contraception. 9 Cromer and colleagues demonstrated that normal adolescent and young adult women on a COC with 30 mcg EE and 1.5 mg desogestrel showed no significant difference in percentage change of bone mineral density at one and two years of use, when compared to age-matched controls. 9 These findings were supported by a similarly designed cohort study in slightly older subjects (18-31 years of age) also demonstrating that 30 mcg EE appeared to be adequate for bone mineral density accrual. 10 Furthermore, other studies found that young women using 20 mcg EE have less increase in bone mineral density than non-users, suggesting that 20 mcg EE may inhibit normal bone development. 11, 12 Current knowledge about the effects of COC's on bone health must be extrapolated to women with KS because there are no published studies in KS patients.
Although lower-dose EE COC preparations may offer a disadvantage in terms of bone mineral density, they may be advantageous in regards to a reduction in hypercoagulability. Among healthy, non-pregnant women between 20-24 years old who do not use COC's, the incidence of thromboembolic events is about 0.3 per 10,000 per year. 13 With the addition of a 30 mcg EE-containing COC, their risk increases by 3-6 fold, with a general consensus that the risk is highest in the first year of use, and remains higher than non-users until discontinuation. 13 Reducing the EE dose to 20 mcg 
mcg to 20 mcg in a COC significantly lowered the levels of clotting factors X and VII in young healthy women. 14 This supports the conclusions articulated by a 1993 prospective randomized trial also finding a significant decrease in hemostasis in 20 mcg EE pills compared to 30 mcg EE. 15 In addition to estrogens, progestins have also been under scrutiny for their role in increasing thrombogenicity among female COC-users. Risk is projected to be even higher than the aforementioned 3-6 fold with COC formulations containing third generation progestins, as opposed to their second-generation predecessors. 16 In the previously mentioned study by Norris and Bonner, when the dose of EE was maintained at 30 mcg, and only the progestin component was manipulated, the women who took a COC containing third generation progestins (i.e. desogestrel) had significantly higher levels of clotting factors VII and X than those women taking a COC with a second generation progestin (i.e. gestodene). 14 Notably, this contradicts one of the earliest studies on this topic, which argued that even though the two most influential coagulation inhibitors (Protein C and AT-III) could not adequately counter the increase in hemostasis induced by COC's, the biological levels did not differ between users of second versus third generation progestins. 17 The attempt to definitively decipher the origins and limitations of the thrombogenicity associated with COC's has dominated much of the contraceptive literature in the past decade and may be an important contributor to our patient's therapy. In summary, decreasing the EE dosage and changing the progestin generation may significantly decrease our patient's chances of another thombotic event, but may also compromise critical bone development.
If we abandon the option of COC's altogether, we are left to evaluate the second widely accepted therapy for hypogonadotropic hypogonadism -pulsatile gonadotropic-releasing hormone (GnRH). GnRH has been used in both males and females. Usually, however, it is reserved for those who desire fertility, a physiologically difficult state for most KS individuals to obtain. 4 It requires an intact pituitarygonadal axis and normal reproductive anatomy. Should we pursue this option with our patient, she is left with her body's own (albeit stimulated) production of gonadotropes and sex steroids and a potentially enhanced state of fertility. The former provides an optimal situation for bone mineral density accrual, while the latter may or may not be desired by the patient.
Although there are no data to suggest that pulsatile GnRH is directly associated with hypercoagulability, it is important to note that the incidence of venous thromboembolism in a normal healthy pregnant woman is 1/1000 (with a 1-2% case mortality), a markedly higher rate than that of healthy females using COC's. 18 Furthermore, should a sexually active female patient elect the GnRH therapy and not desire fertility, we come full circle to the position of needing to provide an effective method of contraception to a young woman with a contraindication to exogenous estrogen therapy. The WHO MEC helps guide this decision again, concluding that the copper IUD bears the lowest risk for our patient; with a risk category of 1-a condition for which there is no restriction for the contraceptive method. 5 The last option besides COC's or GnRH is foregoing hormonal treatment of the hypogonadotropic hypogonadism. This would certainly minimize our patient's chances of future thromboembolisms. However, as discussed above, this risks the premature arrest of sexual maturation, the initiation of menopausal symptoms, and suboptimal bone development and protection. The potential physical and psychological effects that accompany this therapeutic option warrant a thorough and wellinformed discussion between patient and provider.
Conclusions
In summary, we face a difficult situation: a young woman in need of hormonal therapy with a definitive contraindication to such. Our goals are four fold: i) to maintain her secondary sexual development; ii) to prevent the premature induction of menopause, iii) to optimize bone health, and iv) to avoid future thromboembolic events. That being said, our patient appears to have a few options. First, she could remain on the COC's with the consideration of switching to a formulation with a lower EE dosage and/or a second generation progestin. With this choice, we must recognize that although the literature is limited, it appears that bone mineral density could be compromised, meriting emphasis on prophylactic screening and lifestyle measures. Second, the patient could opt for pulsatile GnRH therapy, acknowledging the likelihood of enhanced fertility, and be offered the appropriate contraceptive counseling. Lastly, she could discontinue all hormonal therapy, with knowledge that with the marked decrease in thrombogenicity, comes potentially life-altering changes in sexual development and bone health. More research is needed to better evaluate treatment options for hypogonadal patients needing hormone therapy after a thrombotic event. 
